Back to News
Market Impact: 0.2
Latigo Biotherapeutics Announces CEO Transition to Support the Company's Next Phase of Growth
Source: globenewswire.com
Healthcare & BiotechManagement & GovernanceCompany Fundamentals
Latigo appointed Todd N. Smith, an executive experienced in commercializing pain therapies, as president and CEO. He will lead the company through planned late-stage development and commercialization of its non-opioid pain treatment pipeline; the announcement gives no timing or financial details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
More News
- Tech stocks are suffering their biggest selloff since Covid, as investors see premature end to AI datacenter boom
- Elon Musk's Tesla and SpaceX lose over $420 billion in combined market cap after midterms
- We're raising our price target on Cardinal Health after another stellar quarter of profits
- Costco is taking aim at its May record high — how it got here and where's it going
- Neocloud IREN says $4 billion in annualized revenue being delayed due to customer request
- Tapestry CEO on Earnings Beat, Consumer Outlook